Articles with public access mandates - scott stromeLearn more
Not available anywhere: 1
Anti-CD20 antibody with multimerized Fc domains: a novel strategy to deplete B cells and augment treatment of autoimmune disease
X Zhang, HS Olsen, S Chen, E So, H Zhou, E Burch, EY Mérigeon, ...
The Journal of Immunology 196 (3), 1165-1176, 2016
Mandates: US National Institutes of Health
Available somewhere: 33
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
JJ Park, R Omiya, Y Matsumura, Y Sakoda, A Kuramasu, MM Augustine, ...
Blood, The Journal of the American Society of Hematology 116 (8), 1291-1298, 2010
Mandates: US National Institutes of Health
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients
K Settle, MR Posner, LM Schumaker, M Tan, M Suntharalingam, ...
Cancer prevention research 2 (9), 776-781, 2009
Mandates: US National Institutes of Health
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma
SR Goding, KA Wilson, Y Xie, KM Harris, A Baxi, A Akpinarli, A Fulton, ...
The Journal of Immunology 190 (9), 4899-4909, 2013
Mandates: US National Institutes of Health
Human γδ T lymphocytes induce robust NK cell–mediated antitumor cytotoxicity through CD137 engagement
A Maniar, X Zhang, W Lin, BR Gastman, CD Pauza, SE Strome, ...
Blood, The Journal of the American Society of Hematology 116 (10), 1726-1733, 2010
Mandates: US National Institutes of Health
Isopentenyl pyrophosphate–activated CD56+ γδ T lymphocytes display potent antitumor activity toward human squamous cell carcinoma
AAZ Alexander, A Maniar, JS Cummings, AM Hebbeler, DH Schulze, ...
Clinical Cancer Research 14 (13), 4232-4240, 2008
Mandates: US National Institutes of Health
Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies
W Lin, CJ Voskens, X Zhang, DG Schindler, A Wood, E Burch, Y Wei, ...
Blood, The Journal of the American Society of Hematology 112 (3), 699-707, 2008
Mandates: US National Institutes of Health
Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells
AP Rapoport, NA Aqui, EA Stadtmauer, DT Vogl, YY Xu, M Kalos, L Cai, ...
Clinical cancer research 20 (5), 1355-1365, 2014
Mandates: US National Institutes of Health
RFX transcription factors are essential for hearing in mice
R Elkon, B Milon, L Morrison, M Shah, S Vijayakumar, M Racherla, ...
Nature communications 6 (1), 8549, 2015
Mandates: Swiss National Science Foundation, US National Institutes of Health
Glycoengineering of Human IgG1-Fc through Combined Yeast Expression and in Vitro Chemoenzymatic Glycosylation
Y Wei, C Li, W Huang, B Li, S Strome, LX Wang
Biochemistry 47 (39), 10294-10304, 2008
Mandates: US National Institutes of Health
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010
HCJ Ertl, J Zaia, SA Rosenberg, CH June, G Dotti, J Kahn, LJN Cooper, ...
Cancer research 71 (9), 3175-3181, 2011
Mandates: US National Institutes of Health
Cell Type–Specific Transcriptome Analysis Reveals a Major Role for Zeb1 and miR-200b in Mouse Inner Ear Morphogenesis
R Hertzano, R Elkon, K Kurima, A Morrisson, SL Chan, M Sallin, ...
PLoS genetics 7 (9), e1002309, 2011
Mandates: US National Institutes of Health
Induction of MAGE‐A3 and HPV‐16 immunity by Trojan vaccines in patients with head and neck carcinoma
CJ Voskens, D Sewell, R Hertzano, J DeSanto, S Rollins, M Lee, R Taylor, ...
Head & neck 34 (12), 1734-1746, 2012
Mandates: US National Institutes of Health
A phase I dose escalation trial of MAGE-A3-and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head …
DP Zandberg, S Rollins, O Goloubeva, RE Morales, M Tan, R Taylor, ...
Cancer Immunology, Immunotherapy 64, 367-379, 2015
Mandates: US National Institutes of Health
The role of antagonists of the PD-1: PD-L1/PD-L2 axis in head and neck cancer treatment
SI Pai, DP Zandberg, SE Strome
Oral oncology 61, 152-158, 2016
Mandates: US National Institutes of Health
Identification of potential therapeutic targets in human head & neck squamous cell carcinoma
J Han, M Kioi, WS Chu, JL Kasperbauer, SE Strome, RK Puri
Head & neck oncology 1, 1-9, 2009
Mandates: US National Institutes of Health
Conditional reprogramming for patient-derived cancer models and next-generation living biobanks
N Palechor-Ceron, E Krawczyk, A Dakic, V Simic, H Yuan, J Blancato, ...
Cells 8 (11), 1327, 2019
Mandates: US National Institutes of Health
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer
T Kottke, RM Diaz, K Kaluza, J Pulido, F Galivo, P Wongthida, ...
Molecular therapy 16 (12), 1910-1918, 2008
Mandates: US National Institutes of Health
Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9
SR Boston, R Deshmukh, S Strome, UD Priyakumar, AD MacKerell, ...
BMC cancer 11, 1-12, 2011
Mandates: US National Institutes of Health
Immunotherapy of head and neck cancer: emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
JE Bauman, E Cohen, RL Ferris, DJ Adelstein, DM Brizel, JA Ridge, ...
Cancer 123 (7), 1259-1271, 2017
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program